Biotech ETFs Conquers an Important Technical Hurdle

The SPDR S&P Biotech ETF (NYSEARCA: XBI), one of the largest biotech exchange traded funds, surged last week on news after Roche (RHHBY) acquired gene therapy researcher Spark Therapeutics (ONCE). Roche announced it will pay $4.8 billion to acquire Spark Therapeutics. Spark stocks surged over...